Validity and Reliability of the Integrated Palliative Care Outcome Scale in Asian Heart Failure Patients

Shirlyn Hui-Shan Neo, MBBS, MRCP, MMed(Internal Medicine), FAMS,1,2,* Jasmine Yun-Ting Tan, BA,1 David Kheng-Leng Sim, MBBS, MRCP, MMed(Internal Medicine),3 Elaine Swee-Ling Ng, MSN,4 Julian Kenrick Xingyuan Loh, MB BCh BAO, MRCP, GDip(Palliative Medicine), FAMS,5 Grace Meijuan Yang, MBCh, MA, MRCP, FAMS, MRCP, PhD,1,2 Fliss E.M. Murtagh, MBBS, MRCP, FRCGP, PhD,5 and Yin Bun Cheung, BSSc, MSc, PhD6,7

Abstract

Background: The Integrated Palliative Care Outcome Scale (IPOS) was developed in the United Kingdom for health assessment in advanced illness.

Objectives: To evaluate the validity and reliability of a culturally adapted IPOS (both patient and staff versions) for heart failure (HF).

Design/Setting: We recruited HF patients and staff from a tertiary hospital in Singapore. We collected patient IPOS, New York Heart Association (NYHA) status, Edmonton Symptom Assessment System (ESAS) and Minnesota Living with Heart Failure (MLHF) scores at baseline, and patient IPOS at follow-up. Each baseline patient IPOS was matched with a staff IPOS.

Measurements: Pearson correlation coefficient (r) between ESAS, MLHF, and patient IPOS was calculated to assess construct validity. The two-sample T-test assessed difference in patient and staff IPOS scores across NYHA status and care settings for known-group validity. Internal consistency of patient and staff IPOS was assessed using Cronbach’s alpha (α). Intraclass correlation coefficient (ICC) was used to assess test-retest reliability of patient IPOS and inter-rater reliability between patient and staff IPOS.

Results: Ninety-one patients and 12 staff participated. There was strong convergent validity of total patient IPOS with MLHF ($r = 0.78$) and ESAS ($r = 0.81$). There were statistically significant differences in total IPOS across care settings (patient-IPOS: 8.05, staff-IPOS 13.61) and NYHA (patient-IPOS: 7.52, staff-IPOS 12.71).

There was high internal consistency of total patient ($α = 0.83$) and staff IPOS ($α = 0.88$) and high test-retest reliability of patient IPOS (ICC 0.81). Inter-rater reliability (ICC) ranged between 0.82 and 0.91.

Conclusion: The IPOS was valid and reliable for HF patients in Singapore.

1Division of Supportive and Palliative Care, National Cancer Centre Singapore, Singapore, Singapore.
2Lien Centre for Palliative Care, Duke-NUS Medical School, Singapore, Singapore.
3Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore.
4Nursing Specialty Care Unit, National Heart Centre Singapore, Singapore, Singapore.
5Wolfson Palliative Care Research Centre, Hull York Medical School, University of Hull, Hull, United Kingdom.
6Program in Health Services & Systems Research and Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore.
7Centre for Child, Adolescent and Maternal Health Research, Tampere University, Tampere, Finland.

*Address correspondence to: Shirlyn Hui-Shan Neo, MBBS, MRCP, MMed (Internal Medicine), FAMS, Division of Supportive and Palliative Care, National Cancer Centre Singapore, Level 4, 11 Hospital Crescent, Singapore 169610, Singapore; E-mail: shirlyn.neo.h.s@singhealth.com.sg

© Shirlyn Hui-Shan Neo et al., 2022; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction
The incidence of heart failure (HF) is projected to increase worldwide. Cardiovascular disease is also a significant cause of mortality and morbidity in Singapore and South-East Asia. End-stage HF is characterized by functional decline, physical and psycho-emotional distress, and financial stress. However, these problems are often under-reported by patients and under-identified by health care staff.

Systematic screening of patients with HF, using patient- and staff-reported tools, is one possible way of identifying HF patients who have these needs. Patients can then be referred to palliative care (PC) specialists for support. PC support has been shown to reduce symptom burden and hospitalizations for patients with HF.

The Integrated Palliative Care Outcome Scale (IPOS) was developed in the United Kingdom. It combines the Palliative Care Outcome Scale (POS) (which assesses psycho-emotional, practical, and informational needs) with a symptom module that assesses common symptoms in patients living with serious illnesses. Compared with other tools that are available for PC needs screening, the IPOS is brief, and it has good psychometric properties. In the United Kingdom, the regular use of IPOS during clinical visits helped improve HF patient self-reporting and staff identification of needs.

Assessment tools developed in another country may not be entirely or readily usable in a new setting because of differing socio-economic-cultural contexts and disease-specific impacts. In an earlier study, the team culturally adapted the IPOS for cancer patients in Singapore. This was done through an iterative process of cognitive interviews with patients to adapt the IPOS items in accordance with existing guidelines. However, as patients with HF have a different prevalence of symptoms and needs compared to patients with cancer, this study aimed at evaluating the validity and reliability of the culturally adapted IPOS in patients with HF in Singapore.

Methodology
Study setting
This was a prospective study carried out in the inpatient and outpatient setting of the National Heart Centre Singapore, a large national and regional referral center for patients with cardiac diseases.

Validation process
Participants and recruitment process. The study team consisted of clinicians from a multidisciplinary HF and PC team. The research coordinator screened patients of the study team and patients who were referred to the study team for eligibility. Eligible participants were invited to participate, and those who consented were recruited. Patient participants were at least 21 years old, aware of their diagnosis, had a clinical diagnosis of HF as deemed by their managing cardiologists, and could speak English. English is the most common language spoken at home (48.3% of the population), as in the 2020 Singapore census.

For staff participants, we recruited nursing and physician staff from the multidisciplinary PC and HF teams who directly cared for the recruited patient participants. Staff participants were not part of the study team.

Data collection
Study measures. IPOS: The IPOS is reported by both patients and staff. The patient and staff IPOS are similar except for the last item (not presented in the staff version), which asks the patient if the tool was self-completed or completed with assistance. The first item “What have been your main problems or concerns over the past three days?” required participants to report their main problems and concerns in free text. The IPOS used in this study had an additional descriptor (health, financial, well-being etc.) for the first item, to provide participants with an additional context for answering this question. Apart from the first item, the other items in the IPOS capture patient needs and symptoms over the past three days.

The scores on all items are summed to form a total score, and a higher IPOS total score indicates more needs. The other subscales in the IPOS (physical symptoms, emotional symptoms, communication/practical issues) were derived by summing up the scores of the respective individual items in the respective subscales.

The Edmonton Symptom Assessment System-revised (ESAS-r) assesses physical symptoms such as pain and emotional symptoms such as anxiety.
The item scores for the ESAS can be summed, and a higher total ESAS-r score indicates worse symptoms. For this study, the items related to physical and emotional symptoms were summed to form physical and emotional subscales scores respectively. The Minnesota Living with Heart Failure (MLHF) questionnaire assesses physical and emotional needs that impact a patient’s quality of life. The item scores on the MLHF can be summed, and a higher total score implies a worse quality of life. The MLHF has specific instructions for summing up physical and emotional items to form physical and emotional subscale scores, respectively.

Time points. Data were collected at baseline and follow-up. At baseline, we collected clinical diagnoses from the electronic health records, and patient demographics and New York Heart Association (NYHA) functional status via self-report. Patients filled in the IPOS, the ESAS-r and MLHF. ESAS-r, MLHF, care setting and NYHA status were used as validity criteria for evaluation of the patient IPOS. The primary health care staff caring for the patient was asked to fill in the staff IPOS for his/her patient, such that each patient’s IPOS would be matched by a staff IPOS.

A follow-up patient IPOS was conducted within two weeks after baseline. Patients also answered a question related to change in main concerns and problems: “Since the questionnaire was last completed, thinking about your main problems and concerns, would you say that: things have got much better, things have got a little better, there has been no change, things have got a little worse, things have got much worse?.” This question was used to define eligibility for inclusion for test-retest reliability (those who reported “no change,” “a little better” or “a little worse” would be included).

Statistical analysis plan
We described the percentage of participants who scored the lowest (floor) or highest (ceiling) possible scores to evaluate for any significant floor or ceiling effect (defined as ≥20%) for both the patient and staff IPOS. An overall IPOS score was not generated, if any items within the IPOS were marked “not assessed” or “missing.”

To assess the construct validity (overall validity) of the patient IPOS, we measured the Pearson correlation coefficient ($r$) between the total IPOS scores and the summative scores of the ESAS and MLHF. We also correlated the IPOS subscale scores with the respective subscale scores of the ESAS and the MLHF. To assess known-group validity (ability of IPOS to distinguish between groups), we compared patient and staff IPOS scores in the (1) inpatient setting versus the outpatient setting and (2) those with non- to slight limitation of physical activity (NYHA score 1–2) versus those with marked limitation of physical activity or who were unable to carry out any activity (NYHA score 3–4); using the two-sample t-test.

We calculated Cronbach’s alpha ($\alpha$) to examine the internal consistency (how well the IPOS items measure the same construct) of the patient and staff IPOS. For test–retest reliability (the degree to which IPOS assessments are consistent from one assessment to the next), we calculated the intraclass correlation coefficient (ICC) between the patient IPOS scores at baseline and follow-up for participants who responded that there has been no or minimal change in their main problems and concerns. We also explored the ICC between the patient and staff IPOS across the total scores and subscales for inter-rater reliability (degree of agreement between two raters).

Sample size estimation
To establish convergent validity, we required a minimum sample size of 80 to provide 80% power, at 5% type I error rate, to test a correlation coefficient of 0.4 between the total score of IPOS and ESAS, against a trivial correlation of 0.1. To account for dropouts, at least 90 patients with HF were recruited.

Ethics
This study was reviewed and approved by the Sing-Health Centralized Institutional Review Board (Ref. No. 2019/2344). All participants provided written consent before participation.

Results
Participant characteristics
The demographic characteristics of patients and staff are presented in Table 1. We recruited 91 patients. Corresponding staff IPOS assessments were collected from 12 health care staff. There was a multi-racial distribution of patients, and the Chinese were the most common race (53.9%). The most common cause of HF was ischemic heart disease (56.0%). The mean number of years since HF diagnosis was 6.3 years.

There were nearly equal number of patients in the inpatient setting (46.2%) and outpatient setting (53.9%).
More than half of the patients (67.0%) were able to self-administer the IPOS. The mean total ESAS score was 14.31, and the mean total MLHF was 30.90 for the patient participants. The mean age of staff was 35.4 years. There were eight physicians and four nurses. Staff had a mean of 5.4 years of experience working with HF patients.

### Description of characteristics of patient and staff IPOS

A descriptive summary of the distribution of the patient IPOS is presented in Table 2. There were no missing responses in the patient IPOS. There was a floor effect (reports of no problems at all) across all individual items (from 30.8% for weakness to 87.9% for vomiting), except for the item related to family anxiety. There was a floor effect for the subscale of communication/practical issues but not for the physical and emotional symptom subscales and total patient IPOS scores. There was no ceiling effect for the individual items, subscales, or the total patient IPOS.

For the staff IPOS (described in Table 3), 87 out of 91 (95.6%) of assessments were performed by the HF staff. There were no missing responses except for the individual item for vomiting (1.1%). Gastrointestinal symptoms, drowsiness, mobility, and psychosocial needs were commonly scored by staff as “unable to assess.” There was a floor effect across most individual items, except for those related to family anxiety, peace, information and practical needs. There was a floor effect for the physical, and emotional symptom subscales but not for the communication/practical issues subscale and total staff IPOS scores. There was no ceiling effect for the individual items, subscales, or total scores.

For the patient IPOS (described in Table 4), there was a strong correlation between the total IPOS score and the total MLHF score ($r = 0.78$) and total ESAS score.

### Table 1. Demographics and Characteristics of Participants

| Patient participants ($N = 91$) | Mean (SD)/frequency (%)<sup>a</sup> |
|----------------------------------|----------------------------------|
| **Age, mean (SD)**               | 56.5 (13.5)                      |
| **Gender**                       |                                  |
| Male                             | 67 (73.6)                        |
| Female                           | 24 (26.4)                        |
| **Race**                         |                                  |
| Chinese                          | 49 (53.9)                        |
| Malay                            | 17 (18.7)                        |
| Indian                           | 22 (24.2)                        |
| Others                           | 3 (3.3)                          |
| **Marital status**               |                                  |
| Married                          | 60 (65.9)                        |
| Single                           | 18 (19.8)                        |
| Divorced                         | 7 (7.7)                          |
| Widowed                          | 6 (6.6)                          |
| **Education**                    |                                  |
| No formal education              | 1 (1.1)                          |
| Primary                          | 6 (6.6)                          |
| Secondary                        | 44 (48.4)                        |
| Post-secondary                   | 40 (44.0)                        |
| **Causes of HF**                 |                                  |
| Ischemic heart disease           | 51 (56.0)                        |
| Inflammatory musculopathy        | 3 (3.3)                          |
| Other musculopathy               | 26 (28.6)                        |
| Valvular                         | 1 (1.1)                          |
| Arrhythmia                       | 2 (2.2)                          |
| Congenital                       | 3 (3.3)                          |
| Endocrine                        | 3 (3.3)                          |
| Drug                             | 3 (3.3)                          |
| Others                           | 1 (1.1)                          |
| **No. of years since diagnosis** | 6.3 (5.6)                        |
| **New York Heart Association functional status** (<at point of recruitment>) | |
| 1                                | 36 (40.0)                        |
| 2                                | 34 (37.8)                        |
| 3                                | 20 (22.2)                        |
| 4                                | 0 (0.00)                         |
| **LVEF (at point of recruitment)** | 27.5 (12.3)                     |
| **Mean (SD)**                    | 25 (16)                          |
| Median (IQR)                     |                                  |
| **Mode of administration**       |                                  |
| Interviewer assisted             | 30 (33.0)                        |
| Self                             | 60 (67.0)                        |
| **Setting of administration at baseline** | 42 (46.2)                  |
| Inpatient                        | 49 (53.9)                        |
| Outpatient                       |                                  |

### Table 1. (Continued)

| Health care staff participants ($N = 12$) | Mean (SD)/frequency (%)<sup>a</sup> |
|------------------------------------------|----------------------------------|
| **Age**                                  | 35.4 (3.1)                       |
| **Gender**                               |                                  |
| Male                                     | 4 (33.3)                         |
| Female                                   | 8 (66.7)                         |
| **Designation**                          |                                  |
| Associate Consultant/Consultant          | 6 (50.0)                         |
| Senior Resident/Resident Physician        | 2 (16.7)                         |
| Nurses                                   | 4 (33.3)                         |
| **Years of experience with HF patients** | 5.4 (3.1)                        |

<sup>a</sup>Mean and SD for continuous variables, frequency ($N$) and percent for categorical variables. HF, heart failure; IQR, interquartile range; LVEF, left ventricular ejection fraction; SD, standard deviation.
The physical symptom subscale scores of the IPOS also correlated moderately with the physical symptom subscale scores of the MLHF ($r=0.63$) and the physical symptom subscale scores of the ESAS ($r=0.73$).

The IPOS emotional symptom subscale scores correlated moderately with the MLHF emotional symptoms subscale scores ($r=0.67$) but less so with the ESAS emotional symptom subscale scores ($r=0.50$). The IPOS communication/practical issues subscale scores correlated poorly with ESAS physical symptoms subscale scores ($r=0.33$), providing evidence of divergent validity (degree to which measures that are theoretically un-related are un-related).

| Scale | Domain | Item description | Mean (SD) | % Floor | % Ceiling | % Missing |
|-------|--------|------------------|-----------|---------|-----------|-----------|
| IPOS  | Physical | Pain | 0.58 (1.04) | 68.13 | 4.40 | 0.00 |
|       |         | Breathlessness | 1.08 (1.20) | 43.96 | 4.40 | 0.00 |
|       |         | Weakness | 1.26 (1.13) | 30.77 | 3.30 | 0.00 |
|       |         | Nausea | 0.45 (0.83) | 72.53 | 0.00 | 0.00 |
|       |         | Vomiting | 0.21 (0.64) | 87.91 | 0.00 | 0.00 |
|       |         | Poor appetite | 0.82 (1.06) | 51.65 | 1.10 | 0.00 |
|       |         | Constipation | 0.29 (0.76) | 82.42 | 2.20 | 0.00 |
|       |         | Sore or dry mouth | 0.70 (1.07) | 60.44 | 3.30 | 0.00 |
|       |         | Drowsiness | 0.38 (0.77) | 74.73 | 0.00 | 0.00 |
|       |         | Poor Mobility | 0.74 (0.99) | 56.04 | 1.10 | 0.00 |
|       |         | Domain score | 6.52 (5.42) | 11.00 | 0.00 | 0.00 |
|       | Emotional | Anxious (patient) | 1.13 (1.14) | 35.16 | 4.40 | 0.00 |
|       |         | Anxious (family) | 1.81 (1.29) | 18.68 | 10.99 | 0.00 |
|       |         | Depressed | 0.75 (0.97) | 52.75 | 1.10 | 0.00 |
|       |         | Peace | 1.18 (1.13) | 31.87 | 6.59 | 0.00 |
|       |         | Domain score | 4.87 (3.62) | 9.90 | 0.00 | 0.00 |
|       | Communication/practical | Sharing | 1.14 (1.25) | 42.86 | 6.59 | 0.00 |
|       |         | Having information | 0.89 (1.07) | 47.25 | 3.30 | 0.00 |
|       |         | Practical problems | 1.03 (1.16) | 45.05 | 4.40 | 0.00 |
|       |         | Domain Score | 3.07 (2.63) | 25.30 | 0.00 | 0.00 |
|       | All Items | Total score | 14.45 (9.23) | 2.20 | 0.00 | 0.00 |

IPOS, Integrated Palliative Care Outcome Scale.
Table 4. Pearson Correlation Coefficients (r) of the Patient Rated Integrated Palliative Care Outcome Scale; Edmonton Symptom Assessment System; Minnesota Living with Heart Failure Scores at Baseline (N=91)

| Correlation estimates (r) | MLHF total | MLHF physical | MLHF psychological | ESAS total | ESAS physical | ESAS psychological |
|---------------------------|------------|---------------|--------------------|------------|---------------|-------------------|
| IPOS total                | 0.78       | 0.71          | 0.75               | 0.81       | 0.75          | 0.72              |
| IPOS physical             | 0.61       | 0.63          | 0.48               | 0.71       | 0.73          | 0.55              |
| IPOS emotional            | 0.65       | 0.55          | 0.70               | 0.67       | 0.58          | 0.64              |
| IPOS communication/practical | 0.57     | 0.45          | 0.67               | 0.44       | 0.33          | 0.50              |

All p values were ≤0.001.
ESAS, Edmonton Symptom Assessment System; MLHF, Minnesota Living with Heart Failure.

Inpatients had higher IPOS scores than outpatients, demonstrating the ability of the IPOS to distinguish between patient groups (known group validity) (Table 5). This difference was statistically significant for the total IPOS (p<0.001), IPOS physical symptom subscale (p<0.001), and IPOS emotional symptom subscale (p=0.006). For the comparison of patient IPOS across NYHA strata, differences were also seen, with lower scores among patients with lower NYHA scores. This difference was statistically significant for the total IPOS (p=0.001) and IPOS physical symptom subscale scores (p<0.001).

For the comparison of staff IPOS across care settings, inpatients had higher IPOS scores than outpatients. This was statistically significant for the total staff IPOS, physical and emotional symptoms subscales, and communication/practical issues subscales. In the comparison of staff IPOS across NYHA strata, patients with lower NYHA scores had lower IPOS scores, and this was statistically significant for the total IPOS (p<0.001), physical symptom subscale (p<0.001), and emotional symptom subscale (p=0.039).

Reliability results
The values are presented in Table 6. For the patient IPOS, the total IPOS and emotional subscale of the IPOS demonstrated high internal consistency (x=0.83 and 0.81, respectively) but x was lower for the physical (x=0.76) symptoms and communication/practical issues subscales (x=0.62). For the staff IPOS, the internal consistency was high for the physical symptom subscale (x=0.93), total IPOS (x=0.88), and emotional (x=0.82) symptom subscales but lower for the communication/practical issues subscale (x=0.71).

The mean interval between patient baseline and follow-ups was 4.27 days. The number of patients who participated in follow-up was 71, of whom 22 reported “no change” and 18 reported that their condition was either “a little better” or “a little worse.” For test–retest reliability among the patients who reported “no change,” “a little better” or “a little worse,” the ICC was high (0.81 for the total IPOS) and 0.82–0.85 across the subscales. Of the 91 staff assessments, 15 were complete and were used for comparison with the patient IPOS for inter-rater reliability. The ICC for inter-

Table 5. Known Group Validity Comparisons for Inpatient Versus Outpatient Setting and New York Heart Association Score

| Patient              | Inpatient (N=42) | Outpatient (N=49) | Difference in means | p     | Staff | Inpatient (N=42) | Outpatient (N=49) | Difference in means | p     |
|----------------------|------------------|-------------------|---------------------|-------|-------|------------------|-------------------|---------------------|-------|
| IPOS total           | 18.79 (8.89)     | 10.73 (7.87)      | 8.05                | <0.001| IPOS total | 15.36 (1.37)     | 1.75 (0.63)        | 13.61               | <0.001|
| IPOS physical        | 9.36 (5.73)      | 4.08 (3.71)       | 5.28                | <0.001| IPOS physical | 4.36 (3.32)     | 1.40 (1.87)        | 2.96               | <0.001|
| IPOS emotional       | 5.98 (3.59)      | 3.92 (3.40)       | 2.06                | <0.001| IPOS emotional | 4.31 (3.20)     | 2.46 (2.74)        | 1.89               | <0.001|
| IPOS communication/practical | 3.45 (2.76) | 2.73 (2.49)       | 0.72                | 0.20  | IPOS | 2.92 (2.13)     | 1.78 (1.42)        | 1.12               | 0.006|

| Patient              | NYHA (1–2) (N=70) | NYHA (3–4) (N=20) | Difference in means | p     | Staff | NYHA (1–2) (N=70) | NYHA (3–4) (N=20) | Difference in means | p     |
|----------------------|-------------------|-------------------|---------------------|-------|-------|------------------|-------------------|---------------------|-------|
| IPOS total           | 12.69 (8.97)      | 20.20 (7.87)      | 7.52                | <0.001| IPOS total | 4.17 (1.66)     | 16.88 (1.33)       | 12.71               | <0.001|
| IPOS physical        | 5.23 (4.82)       | 10.85 (5.31)      | 5.57                | <0.001| IPOS physical | 2.06 (2.39)     | 5.25 (3.73)        | 3.19               | <0.001|
| IPOS emotional       | 4.56 (3.74)       | 5.95 (3.10)       | 1.39                | 0.132 | IPOS emotional | 2.93 (3.02)     | 4.55 (2.86)        | 1.62               | 0.0039|
| IPOS communication/practical | 2.90 (2.54) | 3.45 (2.86)       | 0.55                | 0.409 | IPOS communication/practical | 2.17 (1.89)     | 2.85 (1.90)        | 0.68               | 0.172|

NYHA, New York Heart Association.
Discussion

It is important to validate patient-and-staff-reported outcome tools across different cultures and disease populations. This is the first study to assess the measurement properties of the IPOS in patients with HF in Singapore. Our main findings were, first, that the patient and staff IPOS had no ceiling effects but significant floor effects for the individual items. Second, there was evidence of known group validity for both the patient and staff IPOS, and convergent and divergent validity of the patient IPOS. Third, the patient and staff IPOS had good internal consistency. Finally, the patient IPOS had good test–retest reliability.

The low ceiling and high floor effect of the IPOS are advantageous for its use as a screening tool. The use of IPOS as a screening tool was also demonstrated in a cohort of patients with HF in Germany where investigators successfully deployed the IPOS to screen for symptoms and found that clinically relevant symptoms were frequently reported in a significant proportion (75%) of patients.35

With respect to the inter-rater reliability of the IPOS, the number of complete staff responses that could be used for the analysis was less than expected. This could be because most of the staff assessments were conducted by non-PC staff. We postulate that they had documented that they could not assess a fair number of needs on the IPOS either due to a lack of time in the local clinical setting, or that it is generally deemed more important to evaluate physical needs such as breathlessness.

Of note, standard clinical guidelines for cardiologists emphasize the assessment of congestion status, rather than non-cardiac or emotional symptoms.36 A study with health care professionals working with HF patients in the Netherlands also showed that non-PC staff had limited time and were less comfortable in identifying PC needs.37 Further studies should be performed in the future, to understand the reasons for the lack of complete assessments by non-PC staff, and to design strategies that can be used to improve generalist PC education among non-PC staff and to support them with the assessment of the broad PC needs of HF patients. This could improve the utility of the staff IPOS locally for non-PC trained staff.

One of the strengths of this study is that we recruited both patients and staff, and we evaluated the IPOS in a multidisciplinary manner. Second, patients were recruited in a non-PC setting, in contrast to other studies where patients were recruited predominantly from PC services.26 Our findings are unique, as they shed light on how the IPOS could be used to screen the needs of HF patients in a non-PC setting. Lastly, the sample size was also sufficient, ensuring that the study was adequately powered.

The limitations of this study were as follows: First, the IPOS was validated in English, predominately male, and higher educated HF patients. However, this is alike the epidemiology of HF in Asian patients with HF where there is a predominant male population.38 The literacy profile of Singaporeans has also improved over time.25 More Singaporeans have attained post-secondary or higher qualifications and English is now most frequently spoken at home.25 There is value in the validation of tools across settings, diseases, and cultures,39 and future studies could consider the evaluation of IPOS in a more diverse population, including women, non-English speaking, and participants from lower socio-economic statuses.

Second, as we recruited consecutive patients who met the eligibility criteria and consented to participate, sampling bias may have occurred. For example, we did not manage to recruit NYHA class 4 patients. It is possible that they were too symptomatic and not referred for eligibility screening. However, we managed to

Table 6. Test–Retest Reliability of Patient Integrated Palliative Care Outcome Scale and Inter-Rater Reliability of Patient and Staff Integrated Palliative Care Outcome Scale

| Characteristics of IPOS | Intra-class coefficient (test–retest reliability) (N = 40) | 95% Confidence interval | Intra-class coefficient (patient vs. staff IPOS) (N = 15)a | 95% Confidence interval |
|-------------------------|-------------------------------------------------------------|-------------------------|----------------------------------------------------------|-------------------------|
| Physical                | 0.82                                                        | 0.65–0.90b              | 0.84                                                     | 0.70–0.94b              |
| Emotional               | 0.83                                                        | 0.68–0.91b              | 0.85                                                     | 0.71–0.94b              |
| Communication/practical | 0.85                                                        | 0.72–0.92b              | 0.82                                                     | 0.64–0.93b              |
| Total                   | 0.81                                                        | 0.61–0.91b              | 0.91                                                     | 0.83–0.96b              |

*a*Out of 91 IPOS questionnaires done by patient and staff at baseline, 15 staff-patient assessments were used to evaluate inter-rater reliability between patient and staff.

*b*Indicates p-values were statistically significant (<0.05).

http://online.liebertpub.com/doi/10.1089/pmr.2022.0029
recruit a sizeable number of class 3 patients, who have been shown to have similar exercise characteristics to class 4 patients.40

A study using the IPOS in the Japanese population also concluded that NYHA class 3 and 4 patients had similar needs, although worse functional status was associated with more severe symptoms.31 We believe that the IPOS is likely to be valid and reliable in NYHA class 4 patients.

Third, older patients with HF likely have a different spectrum of needs than patients with HF.42,43 However, this study did not have a pre-planned aim to describe the differences in IPOS scores across ages. Further studies should be performed to describe age-specific differences in the needs measured by the IPOS.

Finally, we used the three-day recall period for both inpatient and outpatient settings, as these are similar populations in our model of care. Further studies could be conducted in the local outpatient setting, to understand if the three-or-seven-day recall period would be more appropriate.

In conclusion, the patient and staff IPOS have acceptable validity and reliability in English speaking patients with HF, aged ≥21 years. These findings are alike IPOS validation studies in other settings and disease populations,21,26,44–49 and they support the use of IPOS for screening PC needs of local patients with HF.

Authors’ Contributions

The contributions of the authors are as follows: S.H.-S.N.: conceptualization (lead), methodology (lead), writing-original draft (lead), formal analysis (lead), writing—review and editing (equal); J.Y.-T.T.: software (lead), formal analysis (supporting), review and editing (equal); D.K.-L.S. and E.S.-L.N.: conceptualization (supporting), review and editing (equal); J.K.X.L.: conceptualization (supporting), reviewing and editing (equal); G.M.J.Y.: conceptualization (supporting), methodology (supporting), formal analysis (supporting), writing-review and editing (equal); F.E.M.M.: formal analysis (supporting), writing-review and editing (equal); Y.B.C.: conceptualization (supporting), methodology (supporting), writing-original draft (supporting), formal analysis (supporting), writing-review and editing (equal).

Funding Information

This project was funded by the SingHealth Duke-NUS Academic Medicine Research Grant Call 2018: Special Category (HSR-Health Outcomes); Grant number: AM/HHO001/2018(SRDUKAMR18H1).

Author Disclosure Statement

No competing financial interests exist.

References

1. Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure. Eur J Heart Fail 2020;22(8):1342–1356; doi: 10.1002/ejhf.1858
2. Singapore Statistics. Singapore Heart Foundation. Available from: https://www.myheart.sg/my-heart/heart-statistics/singapore-statistics/ [Last accessed: November 25, 2021].
3. Lam C. Heart failure in Southeast Asia: Facts and numbers. ESC Heart Fail 2015;2:46–49; doi: 10.1002/ehf2.12036
4. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: Lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014;63:1123–1133; doi: 10.1016/j.jacc.2013.11.053
5. Ko Dt, Alter DA, Austin PC, et al. Life expectancy after an index hospitalization for patients with heart failure: A population-based study. Am Heart J 2008;155:324–331; doi: 10.1016/j.ahj.2007.08.036
6. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977–2016; doi: 10.1161/CIRCULATIONAHA.109.192604
7. Solano JP, Golmes B, Higgins J, et al. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006; 31(1):58–69; doi: 10.1016/j.jpainsymman.2005.06.007
8. Ekman I, Celand J, Andersson B. Exploring symptoms in chronic heart failure. Eur J Heart Fail 2005;7:699–703; doi: 10.1016/j.ejheart.2005.07.003
9. Malhotra C, Cheng GS, Tan BC, et al. Living with heart failure: Perspectives of patients from Singapore. Proc Singapore Healthc 2016;25(2):92–97; doi: 10.1177/20105815624121
10. WHO definition of Palliative Care. Available from: http://www.who.int/cancer/palliative/definition/en/ [Last accessed: September 26, 2018].
11. Kernick LA, Hogg KJ, Millerick Y, et al. Does advance care planning in addition to usual care reduce hospitalization for patients with advanced heart failure? A systematic review and narrative synthesis. Palliat Med 2018;20:269216318801162; doi: 10.1177/269216318801162
12. Mentz RJ, O’Connor CM, Granger BB, et al. Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the Pal-HF trial. Am Heart J 2018;204:202–204; doi: 10.1016/j.ahj.2018.07.010
13. Rogers JG, Patel CB, Mentz RJ, et al. Palliative care in heart failure: The Pal-HF randomized, controlled clinical trial. J Am Coll Cardiol 2017;70(3):331–341; doi: 10.1016/j.jacc.2017.05.030
14. Whellan D, Goodlin S, Dickinson M, et al. End of life care in patients with heart failure-consensus statement. J Cardio Fail 2014; 20:121–134; doi: 10.1016/j.cardfail.2013.12.003
15. Jaarsma T, Beattie JM, Ryder M, et al. Palliative care in heart failure: A position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009;11(5):433–443; doi: 10.1093/eurjhf/hfp041
16. Bausewein C, Le Grice C, Simon S, et al. The use of two common palliative outcome measures in clinical care and research: A systematic review of POS and STAS. Palliat Med 2011;25:306–313; doi: 10.1177/2692163109395984
17. Boomsma SM, Couserberg M, Boonyarrra EM, et al. Tools to help healthcare professionals recognize palliative care needs in patients with advanced heart failure: A systematic review. Palliat Med 2021;35(1):45–58; doi: 10.1177/269216320963941
18. Kane PM, Daveson BA, Ryan K et al. Feasibility and acceptability of a patient-reported outcome intervention in chronic heart failure. BMJ Support Palliat Care 2017;7(4):470–479; doi: 10.1136/bmjspcare-2017-001355
19. Kane PM, Ellis-Smith CI, Daveson BA, et al. Understanding how a palliative specific patient reported outcome intervention works to facilitate patient-centred care in advanced heart failure: A qualitative study. Palliat Med 2018;32(1):143–155; doi: 10.1177/0269216317738161
20. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: The new Medical Research Council guidance. BMJ 2008; 337:a1655; doi: 10.1136/bmj.a1655
21. Long VJ, Cheung YB, Qu D, et al. Validity and reliability of the English and translated Chinese versions of the Integrated Palliative Care Outcome Scale (IPOS) in Singapore. BMC Palliat Care 2021;20(1):40; doi: 10.1186/s12904-021-00737-y
22. Antunes B, Brown A, Witt J, et al. The Palliative Care Outcome Scale Family of Measures: Manual for Cross-Cultural Adaptation and Psychometric Validation. London: 2012. Available from: http://prosplan.org/Resources.php [Last accessed: October 26, 2022].
23. The National Heart Centre Singapore. Available from: https://www.nhcs.com.sg/about-us/ [Last accessed: December 12, 2021].
24. Hogan S, Power M, Schulkin J, et al. Referral sampling: Using physicians to recruit patients. Surv Pract 2009;29(1):1–5; doi: 10.2911/sf-2009-0038
25. Singapore Census of Population 2020, Statistical Release. Available from: https://www.singstat.gov.sg/publications/reference/cop2020/cop2020-sr1/census20_stat_release1 [Last accessed: February 21, 2022].
26. Murtagh FE, Ramsenthaler C, Firth A, et al. A brief, patient and proxy reported outcome measurement in advanced illness: Validity, reliability and responsiveness of the Integrated Palliative Care Outcome Scale (IPOS). Palliat Med 2019;33(8):1045–1057; doi: 10.1177/0269216319854264
27. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer 2000;88(9): 2164–2171; doi: 10.1002/(sici)1097-0275(20000901)88:9<2164::aid-cncr24>3.0.co;2-5
28. Yennurajalingam S, Kwon JH, Urbauer DL, et al. Consistency of symptom clusters among advanced cancer patients seen at an outpatient supportive care clinic in a Tertiary Cancer Center. Palliat Support Care 2013;11:473–480; doi: 10.1177/1478951512008879
29. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J 1992;124:1017–1025; doi: 10.1016/0002-8703(92)90986-6
30. Marx RG, Menezes A, Horovitz L, et al. A comparison of two time intervals for test-retest reliability of health status instruments. J Clin Epidemiol 2003;56(8):730–735; doi: 10.1016/s0895-4356(03)00084-2
31. Garin O. Ceiling Effect. In: Encyclopedia of Quality of Life and Well-Being Research. (Michalos AC, ed.). Springer: Dordrecht; 2014.
32. Palliative Care Outcome Scale. How to Score IPOS. Available from: https://pos-pal.org(max/how-to-score.php#:~:text=The%20overall%,range%20from%200%20to%20100%20[Last%20accessed:%20July,27,2022].
33. Asunta P, Viholainen H, Ahonen T, et al. Psychometric properties of observational tools identifying motor difficulties—A systematic review. BMC Pediatr 2019;19(1):322; doi: 10.1186/s12877-019-1567-6
34. Schuer P, Boer C, Schwarte LA. Correlation coefficients: Appropriate use and interpretation. Anesthes Analg 2013;126(5):1763–1768; doi: 10.1213/ANE.0000000000002864
35. Roch C, Palzer J, Zettel T, et al. Utility of the integrated palliative care scale (IPOS): A cross-sectional study in hospitalised patients with heart failure. Eur J Cardiovasc Nurs 2020;19(8):702–710; doi: 10.1177/1474515120919386
36. Heideneich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145(18):e895–e1032; doi: 10.1161/CIR.0000000000100163
37. Ament SMC, van den Broek LM, Everdingen MHJ, et al. What to consider when implementing a tool for timely recognition of palliative care needs in heart failure patients, Palliative Medicine Reports 3:1, 287–295, DOI: 10.1089/pmr.2022.0029
38. Ament B, Spann A, Borilovic J, et al. Understanding the care and support needs of older people: A scoping review and categorisation using the WHO international classification of functional disability and health framework (ICF). BMC Geriatr 2019;19(1):195; doi: 10.1186/s12877-019-1189-9
39. Antunes B, Feuer PD. Validation and cultural adaptation of the Integrated Palliative Care Outcome Scale (IPOS) for the Portuguese population, BMC Palliat Care 2020; 19(1):78; doi: 10.1186/s12904-020-00685-z
40. Sakurai H, Miyashita M, Imai K, et al. Validation of the Integrated Palliative Care Outcome Scale (IPOS)-Japanese Version. Jpn J Clin Oncol 2019;49(3):257–262; doi: 10.1093/jjco/hyy203
41. Sakurai H, Miyashita M, Morita T, et al. Comparison between patient-reported and clinician-reported outcomes: Validation of the Japanese version of the Integrated Palliative Care outcome scale for staff. Palliat Support Care 2021;1–7; In Press; doi: 10.1017/S15478959152000018
42. Bowling A. Do older and younger people differ in their reported well-being? A survey of adults in Britain. Fam Pract 2011;28(2):145–155; doi: 10.1093/fampra/cmq082
43. Ament B, Spann A, Borilovic J, et al. Understanding the care and support needs of older people: A scoping review and categorisation using the WHO international classification of functional disability and health framework (ICF). BMC Geriatr 2019;19(1):195; doi: 10.1186/s12877-019-1189-9
44. Antunes B, Feuer PD. Validation and cultural adaptation of the Integrated Palliative Care Outcome Scale (IPOS) for the Portuguese population, BMC Palliat Care 2020; 19(1):78; doi: 10.1186/s12904-020-00685-z
45. Sakurai H, Miyashita M, Imai K, et al. Validation of the Integrated Palliative Care Outcome Scale (IPOS)-Japanese Version. Jpn J Clin Oncol 2019;49(3):257–262; doi: 10.1093/jjco/hyy203
46. Sakurai H, Miyashita M, Morita T, et al. Comparison between patient-reported and clinician-reported outcomes: Validation of the Japanese version of the Integrated Palliative Care outcome scale for staff. Palliat Support Care 2021;1–7; In Press; doi: 10.1017/S15478959152000018
47. Szeliga M, Kotlinska-Lemieszak A, Jagielski P, et al. Psychometric validation and cross cultural adaptation of the Integrated Palliative Care Outcome Scale in Polish (IPOS-Pol). Palliat Support Care 2022; 20(5):687–693; doi: 10.1017/S1478989521001176
48. Hocaoglu MB, Hepgul N, Tunnard I, et al. Towards patient-centred cancer care: Cross-cultural validity and responsiveness of the Turkish Integrated Palliative Care Outcome Scale. Health Qual Life Outcomes 2020;18(1):312; doi: 10.1186/s12955-020-0153505
49. Sterie AC, Borasio GD, Bernard M, French IPOS consortium. Validation of the French Version of the Palliative Care Outcome Scale. J Pain Symptom Manage 2019;58(5):886–890; doi: 10.1016/j.jpainsymman.2019.07.012

Cite this article as: Neo SH-S, Tan JY-T, Sim DK-L, Ng ES-L, Loh JKK, Yang GM, Murtagh FEM, Cheung YB (2022) Validity and reliability of the integrated palliative care outcome scale in Asian heart failure patients, Palliative Medicine Reports 3:1, 287–295, DOI: 10.1089/pmr.2022.0029

Abbreviations Used

| Abbreviation       | Description                                                                 |
|--------------------|------------------------------------------------------------------------------|
| ESAS               | Edmonton Symptom Assessment System                                           |
| ESAS-r             | Edmonton Symptom Assessment System-revised                                   |
| HF                 | Heart failure                                                                 |
| ICC                | Intraclass correlation coefficient                                            |
| IPOS               | Integrated Palliative Care Outcome Scale                                    |
| IQR                | Interquartile range                                                          |
| MLHF               | Minnesota Living with Heart Failure                                          |
| NYHA               | New York Heart Association                                                  |
| PC                 | Palliative care                                                              |
| POS                | Palliative Care Outcome Scale                                               |
| SD                 | Standard deviation                                                           |

Publish in Palliative Medicine Reports

- Immediate, unrestricted online access
- Rigorous peer review
- Compliance with open access mandates
- Authors retain copyright
- Highly indexed
- Targeted email marketing